Related Experiment Video

Updated: Jan 23, 2026

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
13:25

Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish

Published on: May 15, 2021

6.5K

The alpha-2 receptor agonist dexmedetomidine attenuates vancomycin‑induced acute kidney injury

A Bayram, G N Erkan, G Talih

    Bratislavske Lekarske Listy
    |June 22, 2019
    PubMed
    Abstract

    Keywords:
    dexmedetomidinenephrotoxicityratvancomycinvasoconstriction vasodilation.

    More Related Videos

    Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice09:09

    Ischemia-reperfusion Model of Acute Kidney Injury and Post Injury Fibrosis in Mice

    Published on: August 9, 2013

    40.8K
    Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury15:55

    Intravenous Microinjections of Zebrafish Larvae to Study Acute Kidney Injury

    Published on: August 4, 2010

    23.2K

    Related Concept Videos

    Acute Kidney Injury I: Introduction01:22

    Acute Kidney Injury I: Introduction

    Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
    632
    Acute Kidney Injury II: Pathophysiology01:29

    Acute Kidney Injury II: Pathophysiology

    Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
    962
    Acute Kidney Injury V: Interprofessional Care01:20

    Acute Kidney Injury V: Interprofessional Care

    Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
    307
    Acute Kidney Injury VI: Nursing Management01:22

    Acute Kidney Injury VI: Nursing Management

    Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
    418
    Acute Kidney Injury III: Clinical Manifestations01:29

    Acute Kidney Injury III: Clinical Manifestations

    Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
    851
    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    875